IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting® 2026 an
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting® 2026 an